2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial - Concepedia

Concepedia

Publication | Closed Access

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

498

Citations

15

References

2013

Year

Aron Goldhirsch, Richard D. Gelber, Martine Piccart, Evandro de Azambuja, Marion Procter, Thomas Suter, Christian Jackisch, David Cameron, Harald Weber, Dominik Heinzmann,

Breast OncologyHealth SciencesMedicineClinical TrialsBreast CancerAdjuvant TrastuzumabCancer TreatmentOncologyRadiation OncologyHer2-positive Breast Cancer

References

	Year	Citations

Page 1

Page 1